Tacrolimus

Vitiligo, Pyoderma Gangrenosum, Kidney Transplantation + 12 more

Treatment

3 FDA approvals

20 Active Studies for Tacrolimus

Treatment for

Vitiligo

What is Tacrolimus

TacrolimusThe Generic name of this drug

Treatment SummaryTacrolimus (also known as FK-506 or Fujimycin) is a drug used to weaken a patient’s immune system after organ transplant. It can also be used as a topical treatment for severe atopic dermatitis, severe uveitis after bone marrow transplants, and vitiligo. Tacrolimus was discovered in 1984 from the bacteria Streptomyces tsukubaensis found in a Japanese soil sample. It works by binding to a protein called immunophilin FKBP-12, which then inhibits certain processes within the immune system.

Prografis the brand name

image of different drug pills on a surface

Tacrolimus Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Prograf

Tacrolimus

1994

138

Approved as Treatment by the FDA

Tacrolimus, also called Prograf, is approved by the FDA for 3 uses such as Kidney Transplantation and Kidney .

Kidney Transplantation

Kidney

Immunosuppressive Treatment

Effectiveness

How Tacrolimus Affects PatientsTacrolimus works by blocking a protein (FKBP-12) that helps send signals to T-lymphocytes, which are involved in the body's immune response. It is similar to cyclosporine, but has been shown to be more effective in reducing rejection rates. Tacrolimus is also used to treat eczema, and while it can reduce inflammation like steroids, it is not as strong. It is a great option for treating eczema on the face, as other topical steroids can thin the skin there. For other parts of the body, topical steroids are usually a better option.

How Tacrolimus works in the bodyThe exact way tacrolimus works on atopic dermatitis is uncertain. It is believed to affect lymphocyte activation by forming a complex of tacrolimus, FKBP-12, calcium, calmodulin, and calcineurin. This prevents the movement and activity of a nuclear factor thought to initiate gene expression for lymphokine production. Tacrolimus also stops the gene transcription for various interleukins and other molecules involved in early T-cell activation, as well as blocks the release of pre-formed mediators from mast cells and basophils. Finally, it decreases the presence of a receptor

When to interrupt dosage

The suggested dosage of Tacrolimus is reliant upon the identified condition, such as Vitiligo, Rejection; Transplant, Kidney and Pyoderma Gangrenosum. The magnitude of dosage is contingent upon the delivery approach (e.g. Capsule, gelatin coated - Oral or Topical) specified in the table below.

Condition

Dosage

Administration

Pyoderma Gangrenosum

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Psoriasis

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Vitiligo

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Immunocompromised

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Liver

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Dermatitis, Atopic

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Kidney

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Rheumatoid Arthritis

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Chronic Graft Versus Host Disease

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Oral Lichen Planus

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Immunosuppressive Treatment

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Kidney Transplantation

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Prophylaxis against heart transplant rejection

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Dermatitis, Atopic

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Lung

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Warnings

Tacrolimus Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Tacrolimus may interact with Pulse Frequency

There are 20 known major drug interactions with Tacrolimus.

Common Tacrolimus Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Tacrolimus.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Tacrolimus.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Tacrolimus.

Axitinib

Major

The serum concentration of Axitinib can be increased when it is combined with Tacrolimus.

Bacillus calmette-guerin substrain russian BCG-I live antigen

Major

The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Tacrolimus.

Tacrolimus Toxicity & Overdose RiskThe side effects of overdose on this medication can be serious, such as blurred vision, kidney and liver damage, seizures, uncontrollable shaking, high blood pressure, low levels of magnesium, diabetes, high levels of potassium, itching, trouble sleeping, and confusion. The lowest toxic dose in rats is between 134-194 mg/kg.

image of a doctor in a lab doing drug, clinical research

Tacrolimus Novel Uses: Which Conditions Have a Clinical Trial Featuring Tacrolimus?

147 active clinical trials are analyzing the potential of Tacrolimus to ameliorate Oral Lichen Planus, Pyoderma Gangrenosum and refractory Rheumatoid Arthritis.

Condition

Clinical Trials

Trial Phases

Rheumatoid Arthritis

61 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

Vitiligo

18 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Prophylaxis against heart transplant rejection

0 Actively Recruiting

Lung

0 Actively Recruiting

Pyoderma Gangrenosum

4 Actively Recruiting

Phase 2, Early Phase 1, Phase 3

Psoriasis

0 Actively Recruiting

Chronic Graft Versus Host Disease

29 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1

Oral Lichen Planus

1 Actively Recruiting

Phase 2

Dermatitis, Atopic

0 Actively Recruiting

Kidney Transplantation

0 Actively Recruiting

Liver

0 Actively Recruiting

Immunosuppressive Treatment

0 Actively Recruiting

Immunocompromised

4 Actively Recruiting

Phase 3, Not Applicable, Phase 1

Dermatitis, Atopic

0 Actively Recruiting

Kidney

0 Actively Recruiting

Tacrolimus Reviews: What are patients saying about Tacrolimus?

5Patient Review

1/2/2012

Tacrolimus for Body's Rejection of a Transplanted Organ

I've had zero issues.

5Patient Review

10/13/2007

Tacrolimus for Prevention of Cardiac Transplant Rejection

5Patient Review

12/17/2008

Tacrolimus for Prevent Kidney Transplant Rejection

I had never experienced tremor before, but after starting this medication I quickly felt much better.

5Patient Review

1/2/2011

Tacrolimus for Prevention of Liver Transplant Rejection

This drug has been a life-saver for me. I have nephrotic syndrome, and before taking this pill, I was carrying around a lot of extra fluid in my stomach and other parts of my body. After taking this pill for a few months, I went from 160 pounds back down to my normal weight of 115 pounds. I didn't experience any side effects like I did when my doctor tried Cyclosporine. This drug turned my labs back to normal and made my weekly kidney appointments go from 4-5 times per month down to just once every few months. It's an amazing drug!

5Patient Review

7/31/2017

Tacrolimus for Prevention of Liver Transplant Rejection

I'm five months out from my transplant and I feel great! Thank you so much to my donor.

5Patient Review

4/29/2021

Tacrolimus for Prevention of Liver Transplant Rejection

I've been on this medication for 12 years. I had one liver rejection issue in the beginning, but it was quickly resolved by adjusting my dosage. I'm currently taking 1 mg in the morning and 2 mg at night.

4.7Patient Review

8/16/2008

Tacrolimus for Prevent Kidney Transplant Rejection

After my transplant, I've only experienced one or two rejections. This is due in large part to the Prograf medication I began taking shortly after the surgery.

4.3Patient Review

10/5/2019

Tacrolimus for Prevent of Transplant Rejection

I've had my liver transplants for 25 years and have been on cyclosporine, then tacrolimus. Recently, it's stopped an episode of acute rejection but I've experienced several side effects, including low platelets, headaches, ringing in the ears, difficulty swallowing, heart palpitations and tiredness. Has anyone else been having muscle weakness?

4Patient Review

10/25/2007

Tacrolimus for Prevention of Lung Transplant Rejection

4Patient Review

11/8/2010

Tacrolimus for Prevent of Transplant Rejection

I was originally on a lower dosage of this medication, but it actually ended up raising my IGG levels.

4Patient Review

3/23/2010

Tacrolimus for Prevent Kidney Transplant Rejection

Tacrolimus has been incredibly effective for me since my kidney/pancreas transplant. I've never had any rejection and it's honestly the best drug I'm on right now.

4Patient Review

10/3/2011

Tacrolimus for Prevention of Liver Transplant Rejection

I haven't had any major issues while using tacrolimus. My only complaint is that it caused a slight elevation in creatin levels in my kidneys.

3.7Patient Review

11/14/2013

Tacrolimus for Prevent of Transplant Rejection

One of the more distressing side effects is hair loss. Please be upfront about this potentiality when taking this medication, as it was not initially made clear to me.

3.7Patient Review

11/4/2019

Tacrolimus for Prevent Kidney Transplant Rejection

While this treatment has saved my kidney, the number of awful side effects have really impacted my quality of life.

3Patient Review

3/15/2010

Tacrolimus for Osteoporosis

After 13 hours of not taking prograf, my FK level is 14.6. Is this normal?

2.3Patient Review

1/24/2008

Tacrolimus for Prevent Kidney Transplant Rejection

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about tacrolimus

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is tacrolimus is a steroid?

"Tacrolimus is a prescription non-steroidal medication that is applied to the skin short-term to treat eczema, also known as atopic dermatitis."

Answered by AI

What drug class is tacrolimus?

"Tacrolimus is an immunosuppressant, a class of medication that works by decreasing the activity of the immune system to prevent it from attacking the transplanted organ."

Answered by AI

What does tacrolimus do to skin?

"This drug reduces eczema by weakening the skin's immune system, which decreases the allergic reaction. Tacrolimus is a type of drug called a topical calcineurin inhibitor (TCI)."

Answered by AI

What is tacrolimus is used for?

"Tacrolimus topical is used on the skin to treat moderate to severe atopic dermatitis. Atopic dermatitis is a skin condition where there is itching, redness, and inflammation, much like an allergic reaction."

Answered by AI

Clinical Trials for Tacrolimus

Image of University of Colorado in Aurora, United States.

SBT777101 for Rheumatoid Arthritis

This trial is testing a new treatment called SBT777101 for people with rheumatoid arthritis. The study will look at whether it is safe and how it affects the participants. The treatment will be

University of Colorado (+4 Sites)Mark Eisner, MDSonoma Biotherapeutics, Inc.

Image of Marvel Clinical Research in Huntington Beach, United States.

Placebo +2 More for Vitiligo

Huntington Beach, CA

This trial is studying a medication called ritlecitinib to see how safe and effective it is in treating non-segmental vitiligo, a skin disorder characterized by white patches on the skin

Marvel Clinical Research (+10 Sites)Pfizer CT.gov Call CenterPfizer

Image of University of Miami in Miami, United States.

Horizons Group for Quality of Life

This trial tests if a group therapy program can improve quality of life for people with GvHD.

University of MiamiLara Traeger, PhD

Image of UNC Dermatology and Skin Cancer Center in Chapel Hill, United States.

Baricitinib for Oral Lichen Planus

Chapel Hill, NC

This trial is testing baricitinib to evaluate its effectiveness & safety in treating Oral Lichen Planus & its impact on quality of life.

UNC Dermatology and Skin Cancer CenterDonna Culton, MD, PhDEli Lilly and Company

Have you considered Tacrolimus clinical trials? We made a collection of clinical trials featuring Tacrolimus, we think they might fit your search criteria.

Explore trials for Tacrolimus

Image of Michigan Center for Research Company /ID# 260069 in Clarkston, United States.

Upadacitinib +1 More for Vitiligo

This trial will evaluate if the drug upadacitinib is safe and effective in treating vitiligo, a chronic autoimmune skin disease. 540 participants will be enrolled worldwide to receive either upadacitinib or a placebo in Period A, followed by upadacitinib in Period B.

Waitlist Available

Michigan Center for Research Company /ID# 260069 (+34 Sites)ABBVIE INC.AbbVie

Image of Research Site in Montréal, Canada.

AZD6912 Dose 1 for Rheumatoid Arthritis

Montréal, Canada

This trial will test the safety and effects of increasing doses of AZD6912 given as a single injection under the skin to healthy volunteers.

Research SiteAstraZeneca

Image of University of Alabama At Birmingham Hospital-Whitaker Clinic in Birmingham, United States.

Povorcitinib for Vitiligo

This trial tests a new drug to treat vitiligo, a skin disorder that causes discoloration.

University of Alabama At Birmingham Hospital-Whitaker Clinic (+36 Sites)Incyte Medical MonitorIncyte Corporation

Image of Cahaba Dermatology in Hoover, United States.

Povorcitinib for Vitiligo

This trial tests if a new drug is safe and effective to treat vitiligo, a skin condition.

Cahaba Dermatology (+41 Sites)Incyte Medical MonitorIncyte Corporation

Have you considered Tacrolimus clinical trials? We made a collection of clinical trials featuring Tacrolimus, we think they might fit your search criteria.

Explore trials for Tacrolimus

Image of Clinuvel investigational site in Los Angeles, United States.

SCENESSE + NB-UVB Light for Vitiligo

Los Angeles, CA

This trial will investigate if a drug and light therapy are better than light therapy alone for treating vitiligo on the body and face.

Clinuvel investigational siteClinuvel, Inc.

Image of Icahn School of Medicine at Mount Sinai in New York, United States.

Spesolimab for Pyoderma Gangrenosum

This trial will study if spesolimab can help treat ulcers caused by pyoderma gangrenosum, an autoimmune skin condition, and how it affects the body's immune system.

Icahn School of Medicine at Mount SinaiSaakshi Khattri, MDBoehringer Ingelheim

Image of Anniston Medical Clinic in Anniston, United States.

Imvotamab for Rheumatoid Arthritis

This trial will test if a drug (imvotamab) is safe and tolerable in people with RA who have failed other treatments. Placebos will also be given.

No Cost For Treatment

Anniston Medical Clinic (+13 Sites)Rebecca KunderIGM Biosciences, Inc.

Image of Altoona Center For Clinical Research Site Number : 8400002 in Duncansville, United States.

SAR441566 for Rheumatoid Arthritis

Duncansville, PA

This trial is testing a new drug treatment for rheumatoid arthritis in adults not adequately controlled on methotrexate. It will include 8 visits over 12 wks to assess safety & efficacy.

Altoona Center For Clinical Research Site Number : 8400002 (+7 Sites)Clinical Sciences & OperationsSanofi

Have you considered Tacrolimus clinical trials? We made a collection of clinical trials featuring Tacrolimus, we think they might fit your search criteria.

Explore trials for Tacrolimus

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.

Back to top

Terms of Service Privacy Policy Security